课题基金 / 基金详情

Bacteriophage-derived Inhibitors of the Bacterial RNA Polymerase

Bacteriophage-derived Inhibitors of the Bacterial RNA Polymerase
噬菌体衍生的细菌 RNA 聚合酶抑制剂
批准号:
BB/K000233/1
负责人:
Sivaramesh Wigneshweraraj
金额:
$79.53万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2012
资助国家:
英国
项目状态:
已结题
起止时间:
2012 至 --

项目摘要

项目成果

Sivaramesh Wigneshweraraj的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Many activities that allow organisms to grow, remain alive and viable rely on molecules resembling small machines. In bacteria, the machine which is responsible for accessing information contained in the genes is the RNA polymerase (RNAp), and the process by which the RNAp accesses the information contained in the genes is collectively called gene expression. Therefore, since the RNAp carries out an essential function necessary for the survival of the bacterial cell, the RNAp is also an attractive target for drugs to treat bacterial infections. For instance, the clinically widely used antibiotic rifampicin inhibits the RNAp. However, the frequent emergence of rifampicin-resistant harmful bacteria necessitates research into new compounds to combat bacterial infections by inhibiting the RNAp. Our research focuses on naturally-occurring small proteins which are potent inhibitors of the RNAp and display several of the desirable features for potential development into novel antibiotic-like compounds for inhibiting the RNAp. Here, we will study precisely how three such naturally-occurring RNAp inhibitors, called Gp2, P7 and Gp5.7 inhibit the RNAp from the bacterium Escherichia coli (for Gp2 and Gp5.7) and Xanthomonas orzyae (a bacterial pathogen that causes rice blight). We will employ structural biology to unravel how Gp2, Gp5.7 and P7 look like and interact with the RNAp. We will employ state-of-the art biochemistry and molecular biology to study how Gp2, Gp5.7 and P7 inhibit the RNAp. We will employ a technique called "next-generation sequencing" to study the impact of Gp2 on RNAp activity, i.e. gene expression, at a whole-cell level. In summary, our results will (1) provide novel insights into how the activity of the bacterial RNAp can be controlled, in this case inhibited, by non-bacterial and naturally-occurring factors; (2) establish a solid framework and industrial links for development of novel antibiotic-like lead compounds targeting the bacterial RNAp and (3) provide useful resources for synthetic biology applications.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1038/ncomms5115
发表时间: 2014-06-20
期刊: NATURE COMMUNICATIONS
影响因子: 16.6
作者: [Brown, Daniel R., Barton, Geraint, Pan, Zhensheng, Buck, Martin, Wigneshweraraj, Sivaramesh]
通讯作者: Wigneshweraraj, Sivaramesh
DOI: 10.1126/science.1218716
发表时间: 2012-08-03
期刊: Science (New York, N.Y.)
影响因子: --
作者: [Chakraborty A, Wang D, Ebright YW, Korlann Y, Kortkhonjia E, Kim T, Chowdhury S, Wigneshweraraj S, Irschik H, Jansen R, Nixon BT, Knight J, Weiss S, Ebright RH]
通讯作者: Ebright RH
DOI: 10.1016/j.jmb.2016.08.004
发表时间: 2016-10-09
期刊: JOURNAL OF MOLECULAR BIOLOGY
影响因子: 5.6
作者: [Brown, D. R., Sheppard, C. M., Burchell, L., Matthews, S., Wigneshweraraj, S.]
通讯作者: Wigneshweraraj, S.
DOI: 10.1016/j.molcel.2012.06.013
发表时间: 2012-09-14
期刊: MOLECULAR CELL
影响因子: 16
作者: [James, Ellen, Liu, Minhao, Sheppard, Carol, Mekler, Vladimir, Camara, Beatriz, Liu, Bing, Simpson, Pete, Cota, Ernesto, Severinov, Konstantin, Matthews, Steve, Wigneshweraraj, Sivaramesh]
通讯作者: Wigneshweraraj, Sivaramesh
Characterisation of a novel bacterial ribonucleoprotein complex analogous to eukaryotic processing (P) bodies in Escherichia coli
  • 批准号:
    BB/V000284/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $72.17万
  • 财政年份:
    2021
  • 负责人:
    Sivaramesh Wigneshweraraj
  • 依托单位:
Transcriptional Regulation of a major virulence operon in Staphylococcus aureus: Insights from biochemcial genomic and proteomic studies
  • 批准号:
    BB/I001492/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $42.34万
  • 财政年份:
    2011
  • 负责人:
    Sivaramesh Wigneshweraraj
  • 依托单位:
Mechanism of action of small-molecule inhibitors of bacterial gene transcription.
  • 批准号:
    BB/E023703/1
  • 项目类别:
    Fellowship
  • 资助金额:
    $109.05万
  • 财政年份:
    2007
  • 负责人:
    Sivaramesh Wigneshweraraj
  • 依托单位:
国内基金
海外基金
tRNA-derived small RNA上调YBX1/CCL5通路参与硼替佐米诱导慢性疼痛的机制研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2022
  • 负责人:
    张祥忠
  • 依托单位:
一类DMOA-Derived Meroterpenoid的全合成研究
  • 批准号:
    22071192
  • 项目类别:
    面上项目
  • 资助金额:
    63.0万元
  • 批准年份:
    2020
  • 负责人:
    胡向东
  • 依托单位:
TET1/exosome-derived miR-22-3p/BTG1信号轴在膀胱癌化疗耐药中的作用与分子机制
  • 批准号:
    82072807
  • 项目类别:
    面上项目
  • 资助金额:
    55.0万元
  • 批准年份:
    2020
  • 负责人:
    肖峻
  • 依托单位:
基于寨卡病毒NS1和NS5的海洋微生物中抗病毒化合物的发现
  • 批准号:
    81973204
  • 项目类别:
    面上项目
  • 资助金额:
    56.0万元
  • 批准年份:
    2019
  • 负责人:
    宋福行
  • 依托单位: